English
The long transition from inflammation to proliferation in the wound healing process of diabetes has brought a major challenge, which is exacerbated by persistent inflammatory reaction and insufficient vascularization. To address these issues, a novel nanoenzyme therapy method utilizing asymmetric MnO ₂ - Au mSiO ₂ @ aFGF Janus nanoparticles was designed. Nanoenzymes have mSiO ₂ heads and MnO ₂ extensions, in which acidic fibroblast growth factor (aFGF) is encapsulated to synthesize MnO ₂ - Au mSiO ₂ @ aFGF Janus nanoparticles（ mSAM@aFGF ）. This nanoenzyme system effectively simulates the enzymatic activity of catalase (CAT) and superoxide dismutase (SOD), catalyzing the degradation of reactive oxygen species (ROS) and producing oxygen. In addition, the controlled release of aFGF promotes tissue regeneration and vascularization. In vitro studies have shown that, mSAM@aFGF It can significantly alleviate cellular oxidative stress and enhance cell proliferation, migration, and angiogenesis. An injectable hydrogel based on photocrosslinked hyaluronic acid (HAMA) was developed, which combines the removal of ROS by nanoenzyme and the release of growth factors. HAMA-mSAM@aFGF Hydrogels have shown many benefits in diabetes wound models, including injectability, wound adhesion, hemostasis, anti-inflammatory effect, polarization of macrophage phenotype from M1 to M2, and promotion of angiogenesis. These attributes highlight the potential of this system to promote the transition from chronic inflammation to wound repair and proliferation, and provide a promising treatment strategy for diabetes wound management.
